Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study

Table 3 Changes in LABA/ICS dosages, OCS, SAMA, and LAMA post omalizumab therapy

Duration >120 days	Baseline^a	Follow-up^b	Change from baseline	p-value^c
N = 158	Mean ± SD	Mean ± SD	Mean ± SD	p-value^c
ICS plus LABA
Dose of salmeterol and fluticasone (mcg/day)	302.73 ± 236.28	215.82 ± 243.06	−86.91 ± 198.03	<0.001*
Dose of formoterol and budesonide (mcq/day)	162.72 ± 157.55	102.95 ± 149.38	−59.76 ± 138.84	<0.001*
OCS(tab/day)	1.99 ± 1.27	1.17 ± 1.66	−0.81 ± 1.61	<0.001*
SAMA(bottle/month)	0.44 ± 0.88	0.03 ± 0.21	−0.41 ± 0.86	<0.001*
LAMA(bottle/month)	0.15 ± 0.36	0.13 ± 0.47	−0.01 ± 0.47	0.6935

^aBaseline: 1 year before the index date
^bFollow-up: 2 months before discontinuation (discontinuation of therapy was defined as a gap in therapy of 56 days)
^cFisher’s exact test, *P < 0.05

ISSN: 1471-2466